ArticleScientific reports2022
The abundance of bifidobacterium in relation to visceral obesity and serum uric acid.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Effects ofFrontiers in microbiology · 2025Pooled it
- The Effects of a Prebiotic Formula PromotingInternational journal of medical sciences · 2026Trial
- Gut Microbiome and Metabolome Alterations in Overweight or Obese Adult Population after Weight-LossInternational journal of molecular sciences · 2024Trial
- Metataxonomic strategy to decipher gut bacteriome biomarkers of type 2 diabetes and obesity in Tunisian population.Bioscience reports · 2026Article
- Bifidobacteria: biogeography, host adaptation and ecological functions.Nature reviews. Microbiology · 2026Review
- Microbiota-Gut-Brain Axis Mechanisms in Cognitive Impairment Associated with Central Obesity.Current obesity reports · 2026Review
- Linking visceral fat accumulation to gut microbiota: key bacterial taxa and their roles in the glycogen synthesis pathway.Experimental & molecular medicine · 2026Article
- Branched chain amino acid metabolism and microbiome in adolescents with obesity during weight loss therapy.The Journal of clinical investigation · 2026Observational
- The 2R, 3R isomer of 2, 3-butanediol prevents weight gain and decreases plasma glucose concentration of mice fed a fat-enriched diet.Frontiers in physiology · 2026Article
- Coevolution of Human Diet and Gut Microbiome: Implications for Nutrigenomics and Cross-Population Health.International journal of microbiology · 2026Review
- Article
- The effect of short-term consumption ofExperimental biology and medicine (Maywood, N.J.) · 2026Article
- The Gut Microbiome in Human Obesity: A Comprehensive Review.Biomedicines · 2025Review
- The Regulatory Effects of Exercise and Metformin on Biomarkers in Obesity: A Focus on Uric Acid, Irisin, Adiponutrin, Adropin, and Copeptin.Medicina (Kaunas, Lithuania) · 2025Article
- Article
- Obesity and cancer: unravelling the microbiome's hidden role.Frontiers in nutrition · 2025Review
- Characterization of the gut micro biota in Koreans and investigation of its association with probiotic consumption: implications for microbial ecology and host health.Frontiers in microbiology · 2025Article
- Gut flora influences the hypothalamic-gonadal axis to regulate the pathogenesis of obesity-associated precocious puberty.Scientific reports · 2024Article
- The Impact of Yoyo Dieting and Resistant Starch on Weight Loss and Gut Microbiome in C57Bl/6 Mice.Nutrients · 2024Article
- Association between Gut Microbiota and Metabolic Health and Obesity Status in Cats.Animals : an open access journal from MDPI · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gut microbiome has been shown to play a role in the development of obesity in recent studies. Most of these studies on obesity were based on the BMI classification criteria, which doesn't distinguish Visceral adipose tissue (VAT) from subcutaneous adipose tissue (SAT). Some studies showed that VAT has a higher risk of inducing metabolic diseases than SAT. This study focused on the visceral obesity defined by increased visceral fat area. The present study was designed to investigate the association of visceral obesity with gut predominant microbiota and metabolic status. This study included 372 healthy individuals from medical examination center in Shulan Hangzhou Hospital. Quantitative polymerase chain reaction (q-PCR) technique was used to detect ten kinds of gut predominant bacteria in fresh feces. Visceral fat area (VFA) was measured by the bioimpedance analyzer (INBODY720, Korea). The abundance of Bifidobacterium significantly decreased in the visceral obesity group. Compared with the lean group, Visceral obesity group had significantly higher levels of LDL, TG, FBG, serum uric acid (SUA) and lower levels of HDL. SUA was an independent impact factor for Bifidobacterium. SUA was negatively correlated with Bifidobacterium and positively correlated with VFA. In the mediation analysis, SUA showed significant mediation effect. SUA may be a mediating factor between decreased Bifidobacterium and increased VAT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.